Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Benign Prostatic Hyperplasia Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 – 2027

Table of Content

1. Preface 
    1.1. Report Scope and Market Segmentation 
    1.2. Research Highlights

2. Assumptions and Research Methodology 
    2.1. Assumptions and Acronyms Used
    2.2. Research Methodology

3. Executive Summary
    3.1. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
    3.2. Global Benign Prostatic Hyperplasia Treatment Market: Market Snapshot

4. Market Overview
    4.1. Global Benign Prostatic Hyperplasia Treatment Market: Treatment Overview 
    4.2. Global Benign Prostatic Hyperplasia Treatment Market: Key Industry Developments
    4.3. Market Dynamics
    4.4. Drivers and Restraints Snapshot Analysis
    4.5. Drivers
        4.5.1. Increasing Aging Men Population All Over the World
        4.5.2. Expanding Patient Pool Due to Other Risk Factors
    4.6. Restraints
        4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition
        4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs
    4.7. Opportunities
    4.8. Global Benign Prostatic Hyperplasia Treatment Market Revenue Projections (US$ Mn), 2017–2027

5. Key Insights
    5.1. Clinical Trial Pipeline Analysis
    5.2. U.S. Prevalence of Benign Prostatic Hyperplasia
    5.3. Re-imbursement Scenario
    5.4. Key Merger and Acquisitions
    5.5. Number of Surgeries (Unit Procedures) Performed, 2018
    5.6. Competitive Market Share Analysis, by Company, 2018
    5.7. Average Cost of Benign Prostatic Hyperplasia Treatment 
    5.8. Product/Brand Analysis – 2018
        5.8.1. Urolift
        5.8.2. Rezum

6. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
    6.1. Introduction
    6.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
        6.2.1. Drug Class
            6.2.1.1. Alpha-blockers
            6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
            6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
            6.2.1.4. Others
        6.2.2. Minimally Invasive Surgeries
            6.2.2.1. Transurethral Resection of the Prostate (TURP)
            6.2.2.2. Transurethral Incision of the Prostate (TUIP)
            6.2.2.3. Robotic Surgeries
            6.2.2.4. Transurethral Microwave Thermotherapy (TUMT) 
            6.2.2.5. Prostatic Urethral Lift
            6.2.2.6. Others
        6.2.3. Laser Therapy
        6.2.4. Others
    6.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
    6.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment

7. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
    7.1. Introduction
    7.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
        7.2.1. Hospitals
        7.2.2. Ambulatory Surgical Centers
        7.2.3. Specialty Clinics
        7.2.4. Others
    7.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
    7.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user

8. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
    8.1. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Region, 2017–2027 
        8.1.1. North America
        8.1.2. Europe
        8.1.3. Asia Pacific
        8.1.4. Latin America
        8.1.5. Middle East & Africa
    8.2. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
    8.3. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Region

9. North America Benign Prostatic Hyperplasia Treatment Market Analysis
    9.1. North America Benign Prostatic Hyperplasia Treatment Market 
    9.2. North America Benign Prostatic Hyperplasia Treatment Market Overview
    9.3. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
        9.3.1. Drug Class
            9.3.1.1. Alpha-blockers
            9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
            9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
            9.3.1.4. Others
        9.3.2. Minimally Invasive Surgeries
            9.3.2.1. Transurethral Resection of the Prostate (TURP)
            9.3.2.2. Transurethral Incision of the Prostate (TUIP)
            9.3.2.3. Robotic Surgeries
            9.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
            9.3.2.5. Prostatic Urethral Lift 
            9.3.2.6. Others
        9.3.3. Laser Therapy
        9.3.4. Others
        9.3.5. 
    9.4. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
        9.4.1. Hospitals
        9.4.2. Ambulatory Surgical Centers
        9.4.3. Specialty Clinics
        9.4.4. Others
    9.5. North America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country
        9.5.1. U.S.
        9.5.2. Canada
    9.6. North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
        9.6.1. By Treatment
        9.6.2. By End-user
        9.6.3. By Country

10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis
    10.1. Europe Benign Prostatic Hyperplasia Treatment Market 
    10.2. Europe Benign Prostatic Hyperplasia Treatment Market Overview
    10.3. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
        10.3.1. Drug Class
            10.3.1.1. Alpha-blockers
            10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
            10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
            10.3.1.4. Others
        10.3.2. Minimally Invasive Surgeries
            10.3.2.1. Transurethral Resection of the Prostate (TURP)
            10.3.2.2. Transurethral Incision of the Prostate (TUIP)
            10.3.2.3. Robotic Surgeries
            10.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
            10.3.2.5. Prostatic Urethral Lift 
            10.3.2.6. Others
        10.3.3. Laser Therapy
        10.3.4. Others
    10.4. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
        10.4.1. Hospitals
        10.4.2. Ambulatory Surgical Centers
        10.4.3. Specialty Clinics
        10.4.4. Others
    10.5. Europe Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
        10.5.1. U.K.
        10.5.2. France
        10.5.3. Germany
        10.5.4. Spain
        10.5.5. Italy
        10.5.6. Rest of Europe
    10.6. Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
        10.6.1. By Treatment
        10.6.2. By End-user
        10.6.3. By Country/Sub-region

11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis
    11.1. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Key Findings
    11.2. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Overview
    11.3. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
        11.3.1. Drug Class
            11.3.1.1. Alpha-blockers
            11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
            11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
            11.3.1.4. Others
        11.3.2. Minimally Invasive Surgeries
            11.3.2.1. Transurethral Resection of the Prostate (TURP)
            11.3.2.2. Transurethral Incision of the Prostate (TUIP)
            11.3.2.3. Robotic Surgeries
            11.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
            11.3.2.5. Prostatic Urethral Lift 
            11.3.2.6. Others
        11.3.3. Laser Therapy
        11.3.4. Others
    11.4. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
        11.4.1. Hospitals
        11.4.2. Ambulatory Surgical Centers
        11.4.3. Specialty Clinics
        11.4.4. Others
    11.5. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
        11.5.1. China
        11.5.2. India
        11.5.3. Japan
        11.5.4. Australia & New Zealand
        11.5.5. Rest of Asia Pacific
    11.6. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
        11.6.1. By Treatment
        11.6.2. By End-user
        11.6.3. By Country/Sub-region

12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis
    12.1. Latin America Benign Prostatic Hyperplasia Treatment Market Key Findings
    12.2. Latin America Benign Prostatic Hyperplasia Treatment Market Overview
    12.3. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
        12.3.1. Drug Class
            12.3.1.1. Alpha-blockers
            12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
            12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
            12.3.1.4. Others
        12.3.2. Minimally Invasive Surgeries
            12.3.2.1. Transurethral Resection of the Prostate (TURP)
            12.3.2.2. Transurethral Incision of the Prostate (TUIP)
            12.3.2.3. Robotic Surgeries
            12.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
            12.3.2.5. Prostatic Urethral Lift
            12.3.2.6. Others
        12.3.3. Laser Therapy
        12.3.4. Others
    12.4. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
        12.4.1. Hospitals
        12.4.2. Ambulatory Surgical Centers
        12.4.3. Specialty Clinics
        12.4.4. Others
    12.5. Latin America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
        12.5.1. Brazil
        12.5.2. Mexico
        12.5.3. Rest of Latin America
    12.6. Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
        12.6.1. By Treatment
        12.6.2. By End-user
        12.6.3. By Country/Sub-region

13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis
    13.1. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market 
    13.2. Benign Prostatic Hyperplasia Treatment Market Overview
    13.3. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
        13.3.1. Drug Class
            13.3.1.1. Alpha-blockers
            13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
            13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
            13.3.1.4. Others
        13.3.2. Minimally Invasive Surgeries
            13.3.2.1. Transurethral Resection of the Prostate (TURP)
            13.3.2.2. Transurethral Incision of the Prostate (TUIP)
            13.3.2.3. Robotic Surgeries
            13.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
            13.3.2.5. Prostatic Urethral Lift
            13.3.2.6. Others
        13.3.3. Laser Therapy
        13.3.4. Others
    13.4. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
        13.4.1. Hospitals
        13.4.2. Ambulatory Surgical Centers
        13.4.3. Specialty Clinics
        13.4.4. Others
    13.5. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
        13.5.1. GCC Countries
        13.5.2. South Africa
        13.5.3. Rest of Middle East & Africa
    13.6. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
        13.6.1. By Treatment
        13.6.2. By End-user
        13.6.3. By Country/Sub-region

14. Competitive Landscape (Pharmaceutical Companies)
    14.1. Company Profiles
        14.1.1. Abbott
            14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.1.2. Financials
            14.1.1.3. Recent Developments
            14.1.1.4. Strategy
        14.1.2. Allergan plc
            14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.2.2. Financials
            14.1.2.3. Recent Developments
            14.1.2.4. Strategy
        14.1.3. Astellas Pharma, Inc.
            14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.3.2. Financials
            14.1.3.3. Recent Developments
            14.1.3.4. Strategy
        14.1.4. Asahi Kasei Corporation
            14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.4.2. Financials
            14.1.4.3. Recent Developments
            14.1.4.4. Strategy
        14.1.5. Boehringer Ingelheim GmbH 
            14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.5.2. Financials
            14.1.5.3. Recent Developments
            14.1.5.4. Strategy
        14.1.6. GlaxoSmithKline plc
            14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.6.2. Financials
            14.1.6.3. Recent Developments
            14.1.6.4. Strategy
        14.1.7. Pfizer, Inc.
            14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.7.2. Financials
            14.1.7.3. Recent Developments
            14.1.7.4. Strategy
        14.1.8.  Sanofi
            14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.8.2. Financials
            14.1.8.3. Recent Developments
            14.1.8.4. Strategy
        14.1.9. Teva Pharmaceutical Industries Ltd.
            14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.9.2. Financials
            14.1.9.3. Recent Developments
            14.1.9.4. Strategy
        14.1.10. Merck & Co., Inc.
            14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
            14.1.10.2. Financials
            14.1.10.3. Recent Developments
            14.1.10.4. Strategy

15. Competitive Landscape (Medical Devices/Service Provider Organizations)
    15.1. Company Profiles
        15.1.1. Boston Scientific Corporation
            15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
            15.1.1.2. Financials
            15.1.1.3. Recent Developments
            15.1.1.4. Strategy
        15.1.2. Teleflex Incorporated
            15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
            15.1.2.2. Financials
            15.1.2.3. Recent Developments
            15.1.2.4. Strategy
        15.1.3. Endo International plc
            15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
            15.1.3.2. Financials
            15.1.3.3. Recent Developments
            15.1.3.4. Strategy
        15.1.4. Urologix, LLC
            15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
            15.1.4.2. Financials
            15.1.4.3. Recent Developments
            15.1.4.4. Strategy
        15.1.5. LISA Laser
            15.1.5.1. Overview (HQ, Employee Strength, Business Segments)
            15.1.5.2. Financials
            15.1.5.3. Recent Developments
            15.1.5.4. Strategy
        15.1.6. Olympus Corporation
            15.1.6.1. Overview (HQ, Employee Strength, Business Segments)
            15.1.6.2. Financials
            15.1.6.3. Recent Developments
            15.1.6.4. Strategy

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote